Cargando…
A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
INTRODUCTION: Crohn’s disease (CD) is a chronic and progressive disease in which the long-term management is important. This study sought to assess treatment persistence and dose escalation in the maintenance phase with adalimumab (ADA) or infliximab (IFX) in a Japanese real-world setting. METHODS:...
Autores principales: | Yokoyama, Kaoru, Yamazaki, Kiyotaka, Katafuchi, Miiko, Ferchichi, Sameh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083770/ https://www.ncbi.nlm.nih.gov/pubmed/27664107 http://dx.doi.org/10.1007/s12325-016-0406-6 |
Ejemplares similares
-
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017) -
Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012) -
Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018) -
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020) -
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)